Latest Revenue Forecast News

Althea Group Holdings has sharply downgraded its FY25 financial guidance, citing significant challenges in its medicinal cannabis division and the strategic withdrawal from a vape product initiative. Despite the setback, the company highlights ongoing growth in its recreational cannabis operations and a strategic refocus on capital efficiency.

Mayur Resources has unveiled significant progress on its Central Lime Project, including enhanced production capacity, favorable EPC bids, and advancing offtake negotiations, setting the stage for a Final Investment Decision.

SOCO Corporation Ltd has posted a preliminary 18% increase in first-half FY2025 revenue to $11 million, yet project delays and reduced federal government demand temper full-year growth expectations.

IODM Limited has achieved a significant milestone in its UK Education segment, raising its minimum monthly revenue threshold by 50% to GBP75k and outperforming half-year revenue forecasts.

Associate Global Partners Limited (AGP) reported its strongest quarterly net inflows since 2017, driving funds under management to $1.72 billion amid successful capital raising and robust investment performance.

Develop Global Limited reported a robust increase in cash reserves for the December 2024 quarter, driven by significant financing inflows despite ongoing operational and investing outflows.

PlaySide Studios reports a 21% revenue decline in 1HFY25 and revises full-year guidance downward, citing slower Work for Hire contracts and underperforming original IP sales. Despite short-term challenges, the company remains bullish on upcoming game launches.

Battery Age Minerals has nearly doubled its landholding at the Bleiberg Project in Austria, securing a strategic corridor rich in zinc and germanium. This expansion positions the company to address growing global supply concerns amid China's export restrictions.

Nuix projects solid growth in Annualised Contract Value and revenue for the first half of FY25, despite elongated procurement timelines and increased contract complexity.

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.